Comments
Pharma major Lupin is voluntarily recalling some lots of Suprax, which is used to treat common infections, from the US market on account of discolouration, according to US Food and Drug Administration (USFDA).
The nationwide recall has been initiated by the company on January, 31 this year.
The recall of 64,368 bottles of Suprax (cefixime for oral suspension) was initiated under Class-III which FDA defines as a situation in which use of or exposure to a violative product is not likely to cause adverse health consequences.
“Discoloration; Product may not meet specifications for color description once reconstituted,” the USFDA notification said on the reasons for the Lupin recall.
Financial and other implications of the recall could not be ascertained as an email sent to the Company seeking comments remained unanswered.
Suprax contains cefixime, which is a third-generation oral cephalosporin that has an important role in treating common infections.
Lupin shares closed 0.89 per cent down at Rs 684.70 a piece on BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.